Vnitr Lek 2021, 67(4):195-200 | DOI: 10.36290/vnl.2021.052

Targeted and biological drugs in the treatment of inflammatory rheumatic diseases

Karel Pavelka
Revmatologický ústav, Praha

Cílem přehledové práce je poskytnout přehled o současně v Česku registrovaných biologických a cílených lécích pro léčbu zánětlivých revmatických onemocnění. Konkrétně je podán přehled o léčbě revmatoidní artritidy (RA), ankylozující spondylitidy (AS) a psoriatické artritidy (PsA).

Keywords: targeted and biological therapy, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, JAK inhibitors.

Published: June 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelka K. Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. Vnitr Lek. 2021;67(4):195-200. doi: 10.36290/vnl.2021.052.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509. Go to original source... Go to PubMed...
    2. Swierkot J, Schechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 5: 473-492.
    3. Smolen J, Landewe R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2019 update Ann Rheum Dis 2020; 79: 685-699. Go to original source... Go to PubMed...
    4. Šenolt L, Mann H, Závada J, Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. Česká revmatologie 2017; 1: 8-24.
    5. Smolen J, Aletaha D, Bijlsma JWQ et al. Treating rheumatoid arthritis to target. Recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637. Go to original source... Go to PubMed...
    6. Pavelka K, Nekvindová L, Závada J. Dosažení cíle léčby revmatoidní artritidy je častější u pacientů se střední aktivitou než vysokou aktivitou nemoci v reálné klinické praxi národního registru ATTRA biologické léčby ATTRA. Česká revmatologie 2021; odesláno k publikaci.
    7. Nikiphorou E, Norton S, Young A. Association between rheumatoid arthritis disease activity, progression of functional limitation and long- term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Ann Rheum Dis 2016, 75: 2080-2086. Go to original source... Go to PubMed...
    8. Závada J, Uher M, Sisol K, Forejtová Š, Jarošová K, Mann H, Vencovský J, Pavelka K. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis 2016; 75: 96-102. Go to original source... Go to PubMed...
    9. Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-920. Go to original source... Go to PubMed...
    10. Askling J, Fored CM, Brandt L et al. Risk and case characteristics of tuberculosis in RA associated with tumor necrosis factor in Sweden. Arthritis Rheum 2005; 52(7): 1986-1992. Go to original source... Go to PubMed...
    11. Bongartz T, Sutiton AJ, Sweeting MJ et al. Anti TNF antibody therapy in RA and risk of serious infections and malignance's: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285. Go to original source... Go to PubMed...
    12. Vencovský J et al. Bezpečnost biologické léčby - doporučení České revmatologické společnosti. Česká revmatologie 2009; 3(17): 146-160.
    13. Choy E et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014; 53(12): 2143-2154. Go to original source... Go to PubMed...
    14. Giles JT, Sattar N, Gabriel SE et al. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel group, multicenter, noninferiority, phase 4 clinical trial. Arthritis Rheumatol 2016; 68(Suppl 10): 4357-4359.
    15. Burmester GR, Blanco R, Charles Scoeman C, et al. Tofacitinib in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet 2013; 381: 451-460. Go to original source... Go to PubMed...
    16. Genovese MC, Kremer J, Zamani O et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016; 374: 1243-1252. Go to original source... Go to PubMed...
    17. Smolen J, Pangan AL, Emery P et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to MTX (SELECT-MONOTHERAPY) a randomised, placebo - controlled, double blind phase 3 study www.thelancet. Com 2019; 393(8): 2303-2309. Go to original source... Go to PubMed...
    18. Westhovens R, Taylor OPC, Alten R et al. Filgotinib, an oral JAK selective inhibitor is effective in combination with methotrexate on patients with active rheumatoid arthritis and insufficient response to MTX. Results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 2017; 76: 859-1008. Go to original source... Go to PubMed...
    19. Fleischmann R, Mysler E, Hall S et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL STRATEGY): a phase 3b/4 double blind, head to head, randomised, controlled trial. Lancet 2017; 390: 457-468. Go to original source... Go to PubMed...
    20. Combe B, Kivitz A, Tanaka Y et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate to methotrexate: FINCH 1 52-week results. Ann Rheum Dis 2020; 79(Suppl 1): 316-317. Go to original source...
    21. Taylor PC, Keystone EC, van der Heijde D et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017; 376: 652-662. Go to original source... Go to PubMed...
    22. Fleischmann R, Pangan AL, Song IH et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019; 71(11): 1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28. Go to original source... Go to PubMed...
    23. Curtis JR, Xie F, Yun H et al. Real word comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1843-1847. Go to original source... Go to PubMed...
    24. Wollenhaupt J, Lee EB, Curtis JR et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019; 21(1): 89. doi: 10.1186/s13075-019-1866-2. Go to original source... Go to PubMed...
    25. Cohen SB, van Vollenhoven R, Winthrop K et al. Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analyses From the SELECT Phase 3 Clinical Program. Abstract European Congress of Rheumatology, Madrid, Spain, 2019, THU0167. Go to original source...
    26. Rudwaleit M, van der Heijde D, Landewe R et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68(6): 777-783. Go to original source... Go to PubMed...
    27. van der Heijde D, Ramiro S, Landewe R et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76(6): 978-991. Go to original source... Go to PubMed...
    28. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390(10089): 73-84. Go to original source... Go to PubMed...
    29. Deodhar AS, Gensler LS, Kay J et al. A 52-Week randomized, placebo - controlled trial of certolizumab pegol in non-radiographic axial spondyloarthritis. Arthritis Rheum 2019; 0: pp1-11, doi 10.1002/art.40866. Go to original source... Go to PubMed...
    30. Braun J, Baraliakos X, Deodhar A et al. Secukinumab shows sustained efficacy and low structural progression in AS: 4 year results from the MEASURE I study. Rheumatology (Oxford): 2019; 58: 859-868. Go to original source... Go to PubMed...
    31. Braun J, Baraliakos X, Deodhar A et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2016 Dec 13. pii: annrheumdis-2016-209730. doi: 10.1136/annrheumdis-2016-209730. Go to original source... Go to PubMed...
    32. Sieper J, Deodhar A, Marzo-Ortega H et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2016 Aug 31. pii: annrheumdis-2016-210023. doi: 10.1136/annrheumdis-2016-210023. Go to original source... Go to PubMed...
    33. van der Heijde, Wei J CH-CH, Dougados M et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 2018; 392: 2441-2451. Go to original source... Go to PubMed...
    34. Deodhar A, Poddubnyy D, Pacheco-Tena C et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week, results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheum 2019; 4: 599-611. Go to original source... Go to PubMed...
    35. Deodhar A, van der Heijde D, Gensler LS et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 2020; 395: 53-64. Go to original source... Go to PubMed...
    36. Chandran V, Schentag CT, Gladman DD. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol. 2008; 35(10): 2069-2070. Go to PubMed...
    37. Ramiro S, Smolen JS, Landewé R et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016; 75: 490-498. Go to original source... Go to PubMed...
    38. van der Heijde D, Aletaha D, Carmona L et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015; 74: 8-13. Go to original source... Go to PubMed...
    39. Gossec L, Baraliakos X, Kerschbaumer A et al. EUAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020; 79: 700-712. Go to original source... Go to PubMed...
    40. Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990-999. Go to original source... Go to PubMed...
    41. Mease PJ, McInnes IB, Kirkham B et al. secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015; 373(14): 1329-1339. Go to original source... Go to PubMed...
    42. McInnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderte-to-severe psoriatic arthritis: a 24 week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73(2): 349-356. Go to original source... Go to PubMed...
    43. Mease PJ, Kavanaugh A, Reimold A et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 future 1 study. ACR Open Rheumatol 2020; 2: 18-25. Go to original source... Go to PubMed...
    44. Mease PJ, Smolen JS, Behrens F et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020; 79: 123-131. Go to original source...
    45. Cutolo M, Myerson GE, Fleischmann RM et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial.Rheumatol 2016; 43: 1724-1734. Mease P, Hall S, FitzGerald O et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 2017; 377: 1537-1550. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.